Skip to main content

Leukemia, Acute Lymphocytic (ALL), Adolescent & Young Adult (ACCL16N1CD)

Documentation and Delivery of Guideline- Consistent Treatment in Adolescent and young Adult (AYA) Acute Lymphoblastic Leukemia



This research trial studies cancer care delivery in adolescent and young adult patients with acute lymphoblastic leukemia. Surveying institutions, evaluating delivery of care at the patient level and seeking input from healthcare providers may help doctors increase rates of adherence to National Comprehensive Cancer Network (NCCN) treatment guidelines. It may also improve care for adolescent and young adult patients with acute lymphoblastic leukemia.

Key Inclusion Criteria

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.

  • Newly diagnosed with either Ph- or Ph+ ALL between January 1st, 2012 and December 31st, 2016
  • Both diagnosed and initially treated at the participating National Cancer Institute Community Oncology Research Program (NCORP) institution during induction and post-induction therapy (PIT)
  • Aim 3: Healthcare professional currently employed at a participating NCORP institution
    • Eligible healthcare providers include but are not limited to: physicians, registered nurses (RNs), nurse practitioners, physician assistants, patient advocates, social workers, pharmacists and clinical research associates (CRAs)
  • Aim 3a: Direct involvement in the care of AYA ALL patients
Key Exclusion Criteria

Key Exclusion Criteria

A patient will not be eligible for participation in this study if any of the following criteria apply.

  • Diagnosis of secondary ALL
  • Diagnosis of mixed lineage acute leukemia
  • Diagnosis of acute leukemia of ambiguous lineage (ALAL)
  • Diagnosis of Burkitt's leukemia
  • Transfer of care to another institution during induction or post-induction therapy (PIT)
  • Aim 3: Trainee
Learn More

Learn More

To learn more, visit ClinicalTrials.Gov

Study Type

Phase III

Principal Investigator(s)

Roberto Ferro, MD


Children's Oncology Group